News | December 08, 2022
Wockhardt promoters sell stake
The proceeds of the issue has been/will be reinvested in the company and to meet its own business requirements.
The proceeds of the issue has been/will be reinvested in the company and to meet its own business requirements.
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner
WCK 5222 is a Super-drug which is entirely a new class of antibiotic known as "?-lactam ENHANCER".
Parkinson’s is not limited to old people, even youngsters can suffer from this disease
The facility will produce 150 million vaccine doses per year
The USFDA has granted a qualified infectious disease product (QIDP) designation to WCK 6777, which signifies its ability to meet unmet medical needs and facilitates a faster approval process
The facility is spread across 215000 sq. feet and provides super-speciality care
Wockhardt has entered into an agreement with Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against Covid-19
The Board of Directors of Wockhardt have approved the unaudited consolidated financial results for the period ended September 30, 2021.
Subscribe To Our Newsletter & Stay Updated
